Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1494 of 5804
-
Can a video call help Parkinson's patients swallow safely?
Symptom relief Recruiting nowAirway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address …
Phase: PHASE2 • Sponsor: Teachers College, Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
New drug trial offers hope for advanced cancer patients
Disease control Recruiting nowIn this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metast…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
AI and blood tests join forces to catch lung cancer sooner
Diagnosis OngoingThe study will use a blood sample collected from participants to: * Develop new ways of finding and diagnosing lung health problems, such as lung cancer. * Develop tools which make it easier to screen people with possible lung health problems, diagnose problems earlier and with …
Sponsor: University of Oxford • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Can a heart pill protect cancer Survivors' hearts?
Disease control Recruiting nowTo determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New antibody weapon targets tough lymphoma
Disease control OngoingIn this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MT…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Simple blood draw could replace invasive biopsies for cervical cancer
Diagnosis Recruiting nowHuman papilloma virus-related gynecologic malignancies affect over 20,000 women in the United States, and over half a million women globally each year. In addition, approximately 200,000 women are diagnosed with high-grade cervical dysplasia, a pre-cancerous tumor. There is no cu…
Phase: NA • Sponsor: Northwell Health • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Weekly shot could replace daily needles for kids with growth disorders
Disease control OngoingThe study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic short stature. The purpose of the study is to see how well treatment with somapacitan works compared to treatment with Norditropin®. S…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo aims to control advanced kidney cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior the…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New heat treatment may cut cancer pain without extra drugs
Symptom relief CompletedThis study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control …
Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New targeted drug BL-M07D1 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowIn phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug shows promise for Long-Term control of esophagus inflammation
Disease control CompletedThis study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can kids get vaccinated sooner after cancer? new study tests earlier shots
Knowledge-focused Recruiting nowPediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy s…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Could poop pills heal gut damage in rare immune disease?
Disease control Recruiting nowBackground: Chronic granulomatous disease (CGD) weakens the body's defense against germs. CGD can also damage the colon. It can cause inflammation (colitis) that disrupts the good bacteria. Placing good bacteria from donor stool into the intestine of a person with CGD (called fe…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
High-Dose exercise may speed concussion recovery in teens
Symptom relief Recruiting nowAerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophy…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
One pill to tackle two heart risks: new combo therapy tested
Disease control CompletedThe goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
Phase: PHASE3 • Sponsor: Celltrion Pharm, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced colorectal cancer: first human trial launches
Disease control Recruiting nowThe purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * St…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedAOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug cocktail targets Hard-to-Treat amyloidosis
Disease control OngoingThis phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abno…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for indian men with aggressive prostate cancer: darolutamide trial launches
Disease control Recruiting nowResearchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hor…
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New eyedrop shows promise for Mite-Related dry eye
Disease control CompletedThe purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
Phase: PHASE2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC